Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA.

4508 Background: Clinical stage I seminoma testicular cancer is the most frequent presentation of testicular cancer. Current treatment option include surveillance (SURV) or adjuvant chemotherapy. Following a large randomized phase III study, 1 course of adjuvant carboplatin (AC) AUC7 became the preferred adjuvant treatment option. Methods: A risk-adapted protocol (SWENOTECA VII) was initiated in 2007, based on the proposed risk factors; invasion of rete testis and tumor size >4cm. Patients with 0-1 risk factor were recommended SURV, but could choose 1 course of AC (AUC7). Patients with 2 risk factors were recommended 1 course of AC, but could choose SURV. We also report treatment results from patients treated with AC in an earlier protocol during 2004-2007. Results: 839 patients were included in the SWENOTECA VII protocol. In addition 225 patients were treated with AC before 2007. Median follow-up is 4.0 years, 3.6 years for patients on SURV and 4.2 years for patients treated with AC. In total 675 patient...